Combination immunotherapy dosing regimen for immune checkpoint blockade
The present disclosure provides a method of treating cancer with a priming dose of combination immunotherapy comprising IL-2 (e.g., extended-PK IL-2), an immune checkpoint inhibitor, a tumor targeting antibody or integrin-binding polypeptide, and optional cancer vaccine, administered prior to maintenance doses of immune checkpoint inhibitor therapy. The methods of the disclosure can be used to treat a broad range of cancer types.
1. A method for treating a cancer in a subject, comprising administering to the subject:
(a) a priming dose comprising (i) interleukin (IL)-2, (ii) an immune checkpoint inhibitor polypeptide, and (iii) an integrin-binding polypeptide, wherein the priming dose induces or enhances an anti-tumor immune response in the subject; and
(b) at least one maintenance dose comprising an immune checkpoint inhibitor polypeptide,
wherein the priming dose is administered at least four days prior to the at least one maintenance dose,
thereby treating cancer in the subject.
2. The method of claim 1 , wherein IL-2 is Proleukin.
3. The method of claim 1 , wherein IL-2 is administered at a dose of less than 14 MIU/m 2 , less than 12 MIU/m 2 , less than 10 MIU/m 2 , less than 8 MIU/m 2 , less than 6 MIU/m 2 , less than 4 MIU/m 2 , or less than 2 MIU/m 2 .
4. The method of claim 1 , wherein IL-2 is an extended pharmacokinetic (PK) IL-2.
5. The method of claim 4 , wherein the extended-PK IL-2 comprises a fusion protein.
6. The method of claim 5 , wherein the fusion protein comprises an IL-2 moiety and a moiety selected from the group consisting of an immunoglobulin fragment, an immunoglobulin Fc domain, human serum albumin, and Fn3.
7. The method of claim 4 , wherein the extended-PK IL-2 comprises an IL-2 moiety conjugated to a non-protein polymer.
8. The method of claim 1 , wherein the immune checkpoint inhibitor polypeptide of the priming dose is:
(i) an antibody or antibody fragment targeting PD-1, PD-L1, CTLA-4, LAG3, TIM3, or a member of the B7 ligand family;
(ii) an antibody or antibody fragment targeting PD-1;
(iii) an antibody or antibody fragment targeting PD-1 selected from the group consisting of: nivolumab and pembrolizumab;
(iv) an antibody or antibody fragment targeting PD-L1;
(v) an antibody or antibody fragment targeting PD-L1 selected from the group consisting of: atezolizumab, avelumab, and durvalumab;
(vi) an antibody or antibody fragment targeting CTLA-4; or
(v) an antibody or antibody fragment targeting CTLA-4 selected from the group consisting of: tremelimumab and ipilimumab.
9. The method of claim 1 , wherein the integrin-binding polypeptide comprises an integrin-binding loop and a knottin polypeptide scaffold, and wherein the integrin-binding polypeptide binds to a tumor-associated integrin selected from the group consisting of α v β 3 , α v β 5 , α 5 β 1 , or combination thereof.
10. The method of claim 1 , wherein the integrin-binding polypeptide is operably linked to an immunoglobulin Fc domain.
11. The method of claim 9 , wherein the knottin polypeptide scaffold comprises at least three cysteine disulfide linkages or crosslinked cysteine residues, and wherein the integrin-binding loop is adjacent to cysteine residues of the knottin polypeptide scaffold, or wherein the knottin polypeptide scaffold is derived from a knottin peptide selected from the group consisting of EETI-II, AgRP, and agatoxin.
12. The method of claim 9 , wherein the knottin polypeptide scaffold is derived from EETI-II and the integrin-binding loop comprises the sequence X 1 X 2 X 3 RGDX 7 X 8 X 9 X 10 X 11 (SEQ ID NO: 136), wherein each X represents any amino acid, wherein the loop is inserted between 2 cysteine residues in the EETI-II sequence and replaces the native EETI-II sequence.
13. The method of claim 1 , wherein the integrin-binding polypeptide comprises;
(i) the amino acid sequence set forth SEQ ID NO: 42 or 43, wherein X1 is selected from the group consisting of A, V, L, P, F, Y, S, H, D, and N; X2 is selected from the group consisting of G, V, L, P, R, E, and Q; X3 is selected from the group consisting of G, A, and P; X7 is selected from the group consisting of W and N; Xg is selected from the group consisting of A, P, and S; X9 is selected from the group consisting of P and R; X10 is selected from the group consisting of A, V, L, P, S, T, and E; and Xn is selected from the group consisting of G, A, W, S, T, K, and E;
(ii) an amino acid sequence selected from the group consisting of SEQ ID NOs: 59-125; or
(iii) the amino acid sequence of SEQ ID NO: 86 or 88.
14. The method of claim 10 , wherein the integrin-binding polypeptide operably linked to an immunoglobulin Fc domain comprises the amino acid sequence of SEQ ID NO: 48, 49, 50, or 51.
15. The method of claim 1 , wherein the immune checkpoint inhibitor polypeptide of the maintenance dose is:
(i) an antibody or antibody fragment targeting PD-1, PD-L1, CTLA-4, LAG3, TIM3, or a member of the B7 ligand family;
(ii) an antibody or antibody fragment targeting PD-1;
(iii) an antibody or antibody fragment targeting PD-1 is selected from the group consisting of: nivolumab and pembrolizumab;
(iv) an antibody or antibody fragment targeting PD-L1;
(v) an antibody or antibody fragment targeting PD-L1 is selected from the group consisting of: atezolizumab, avelumab, and durvalumab;
(vi) an antibody or antibody fragment targeting CTLA-4; or
(vii) an antibody or antibody fragment targeting CTLA-4 is selected from the group consisting of: tremelimumab and ipilimumab.
16. The method of claim 1 , wherein the maintenance dose comprises a second different immune checkpoint inhibitor polypeptide.
17. The method of claim 16 , wherein the second different immune checkpoint inhibitor polypeptide is an antibody or antibody fragment targeting PD-1, PD-L1, CTLA-4, LAG3, TIM3, or a member of the B7 ligand family.
18. The method of claim 16 , wherein the maintenance dose comprises an antibody or antibody fragment targeting PD-1 and an antibody or antibody fragment targeting CTLA-4.
19. The method of claim 1 , wherein the priming dose:
(i) induces infiltration of immune cells in a tumor, wherein the immune cells are CD8+ T cells, natural killer cells, dendritic cells, or any combination thereof;
(ii) induces or promotes tumor cell apoptosis;
(iii) induces or promotes tumor cell immunogenic cell death;
(iv) induces migration of dendritic cells to a tumor draining lymph node;
(v) induces tumor antigen uptake by dendritic cells in the tumor, tumor draining lymph nodes, or both;
(vi) induces expression of at least one cytokine or chemokine;
(vii) induces expression of at least one cytokine or chemokine selected from the group consisting of: IFN-γ, IL-1β, MIP-1α, G-CSF, Eotaxin, IP-10, MIG, M-CSF, MCP-1, RANTES, IL-12, GM-CSF, MIP-2, TNFα, IL-5, MIP-1β or any combination thereof;
(viii) induces expression of FLT3L and XCL1 in a tumor;
(ix) induces or promotes normalization of vasculature within the tumor; or
(x) a combination of (i)-(ix).
20. The method of claim 1 , wherein the priming dose is administered five days, six days or seven days before the at least one maintenance dose.
21. The method of claim 1 , wherein (i), (ii) and (iii) of the priming dose:
(i) are formulated in the same composition;
(ii) are formulated in different compositions, wherein (i), (ii), and (iii) are administered simultaneously; or
(iii) are formulated in different compositions, wherein the (i), (ii), and (iii) are administered sequentially.
22. The method of claim 21 , wherein the compositions are administered by the same route of administration, or wherein the compositions are administered by different routes of administration.
23. The method of claim 1 , wherein the priming dose and at least one maintenance dose are administered by the same route of administration, or by different routes of administration.
24. The method of claim 1 , wherein the cancer comprises tumor cells expressing a tumor-associated integrin, and wherein the integrin-binding polypeptide binds to the tumor cells expressing the tumor-associated integrin.